


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**  
**領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

**SUPPLEMENTAL ANNOUNCEMENT**

**IN RELATION TO THE CIRCULAR IN RESPECT OF**  
**(1) AMENDMENT OF THE TERMS AND CONDITIONS OF THE**  
**CONVERTIBLE BONDS;**  
**(2) GRANT OF SPECIFIC MANDATE TO ISSUE CONVERSION SHARES;**  
**(3) CONNECTED TRANSACTION AT SUBSIDIARY LEVEL;**  
**AND**  
**(4) NOTICE OF SPECIAL GENERAL MEETING**

Reference is made to the circular of the Company dated 12 June 2023 in respect of, among other things, amendment of the terms and conditions of the Convertible Bonds (the “**Circular**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As disclosed in the Circular, as at the Latest Practicable Date, the Company did not have any arrangement to undertake fund raising activities and did not have any plans to undertake fund raising activities in the near future.

The Company would like to supplement that subsequent to the publication of the Circular, on 12 June 2023, the Company was approached by a potential investor with an expression of interest to subscribe for new Shares. The Company will make further announcement(s) in this regard as and when appropriate and in accordance with the Listing Rules.

The Board confirms that the above supplemental information does not affect other information contained in the Circular and save as disclosed above, all other information set out in the Circular remain unchanged.

By order of the Board  
**Innovative Pharmaceutical Biotech Limited**  
**Tang Rong**  
*Executive Director*

Hong Kong, 14 June 2023

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).*